Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
How do you decide on first line treatment for a patient with metastatic colon cancer with dMMR, a HER2 mutation and no mutations in KRAS or BRAF?
Related Questions
Should immunotherapy be added to standard of care neoadjuvant chemotherapy in borderline resectable MSI-H adenocarcinoma of pancreas?
Would you offer consolidative full dose chemo-RT for local residual pancreatic disease in a patient with stage IV pancreatic adenocarcinoma with excellent response after induction chemotherapy?
Would you use triplet chemotherapy FLOT in lieu of chemoRT for patients with localized esophageal squamous cell carcinoma?
How does the management of POLE mutated colorectal cancer differ from that of dMMR/MSI high disease?
What factors (age, PS) do you consider to avoid using FLOT in the perioperative treatment of gastric and esophageal cancers?
What do you recommend for patients with stage 3 MSI-H colorectal cancer who are ineligible for oxaliplatin-based adjuvant therapy?
What are your top takeaways from ASCO GI 2024?
Would you still offer adjuvant chemo at 24 weeks post Whipple for a pT1c pN2 cM0 neg margins ampullary adenocarcinoma?
For patients with large, partially or nearly obstructing rectal cancers, how do you sequence TNT in order to avoid complete obstruction and surgical diversion?
When a patient with pancreatic cancer received neoadjuvant chemo + chemo-RT, how do you manage an in-field, post operative positive margin?
